New Abbott Sensor Could Prevent Deadly Diabetes Complications Before They Strike

Diabetic ketoacidosis (DKA) is becoming a growing concern for people with both Type 1 and Type 2 diabetes. New data shows hospitalisation rates for DKA have risen sharply in recent years, with many cases going unnoticed until severe. Now, Abbott has developed a new sensing technology to help detect rising ketone levels before they escalate into a crisis. DKA happens when the body lacks insulin and starts breaking down fat for energy. This process produces high levels of ketones, which can spiral into a life-threatening condition within hours. If untreated, it may lead to coma or even death.

Traditionally linked to Type 1 diabetes, DKA is now increasingly affecting those with Type 2 diabetes. Between 2017 and 2024, hospital admissions for DKA in people with Type 1 diabetes rose by around 24%. Among young people with either type, DKA now accounts for nearly 60% of all diabetes-related hospital stays. Early detection remains a challenge. Many people with diabetes don’t recognise DKA symptoms, which can overlap with common illnesses like the flu. Even when glucose levels appear stable, ketones can rise dangerously. Current continuous glucose monitors (CGMs) don’t track ketones, leaving a critical gap in early warning. The problem extends beyond awareness. DKA is often underreported in adults with Type 2 diabetes, leading to delayed treatment. When diagnosed after admission, it results in longer hospital stays and higher medical costs.

Abbott’s new dual glucose-ketone sensing technology aims to close this gap by alerting users to rising ketone levels. The device could help prevent DKA before it becomes severe. With hospitalisation rates climbing, early detection may reduce complications and healthcare burdens for those at risk.